Exosome medicine company Exopharm Limited (ASX:EX1) advises that it will be presenting the attached Investor Deck at today’s Stockhead V-Con on Biotechs.
Nyrada Inc have this morning announced encouraging results from an invivo study of their PCSK9i cholesterol inhibitor combined with Pfizer’s statin Lipitor. The results in a mouse model showed [...]
Incannex to develop IHL-216A formulation for use in pivotal clinical trials required for product registration
Vectura is a state-of-the-art contract development and manufacturing organisation (CDMO) that specialises in the development and manufacture of inhaled drugs and their associated delivery products.
Remote communications innovator Harvest Technology Group Limited (ASX:HTG) (Harvest, Company) is pleased to advise that it has executed a formal Stock Purchase Agreement (SPA) for the acquisition [...]
• New lead drug candidate NYR-BI01 advances to efficacy studies in collaboration with the Walter Reed Army Institute of Research (WRAIR) • NYR-BI01 showed improved potency, along with excellent [...]
Exopharm has been granted a patent for its LEAP technology by Russia’s Patent Office. The patent underpins a core Exopharm technology that enables the large-scale purification of exosome [...]